Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080882 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT04080882 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 80 participants.
The verdict
NCT04080882, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.
Interventions
- OTHER Placebo
- BIOLOGICAL AbobotulinumtoxinA dose 3
- BIOLOGICAL AbobotulinumtoxinA dose 1
- BIOLOGICAL AbobotulinumtoxinA dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2020-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04080882
The ClinicalTrials.gov registry entry for NCT04080882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04080882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04080882 about?
NCT04080882 is a clinical study titled "Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands". Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.
What is the current status of trial NCT04080882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2019-09-25. Estimated completion is 2020-06-04.
What interventions are being tested in trial NCT04080882?
The interventions under investigation include: Placebo (OTHER), AbobotulinumtoxinA dose 3 (BIOLOGICAL), AbobotulinumtoxinA dose 1 (BIOLOGICAL), AbobotulinumtoxinA dose 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04080882?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.